| Drug ID: | Drug11 |
|---|---|
| Drug Name: | Berberine |
| CID: | 2353 |
| DrugBank ID: | DB04115 |
| Modality: | Small Molecule |
| Groups: | experimental |
| US Approved: | NO |
| Other Approved: | NO |
| Identifier: | NCT02962245 |
| Molecular Formula: | C20H18NO4+ |
| Molecular Weight: | 336.4 g/mol |
| Isomeric SMILES: | COC1=C(C2=C[N+]3=C(C=C2C=C1)C4=CC5=C(C=C4CC3)OCO5)OC |
| Synonyms: | berberine; 2086-83-1; Umbellatine; Berberin; Berbericine; Majarine; Thalsine; Umbellatin; Berberone; Benzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium, 5,6-dihydro-9,10-dimethoxy- |
| Phase 0: | 2 |
| Phase 1: | 4 |
| Phase 2: | 15 |
| Phase 3: | 15 |
| Phase 4: | 21 |
| Description: | An alkaloid from Hydrastis canadensis L., Berberidaceae. It is also found in many other plants. It is relatively toxic parenterally, but has been used orally for various parasitic and fungal infections and as antidiarrheal. [PubChem] |
Molecular Structure
Knowledge Graph
| dtID | CID | Compound Name | Gene ID | Gene Name | Species | PubMed IDs | Action |
|---|---|---|---|---|---|---|---|
| dt90 | 2353 | Berberine | 7124 | TNF | Rattus norvegicus (Norway rat) | 25600690 | Berberine inhibits the reaction [mercuric chloride results in increased expression of TNF protein] |
| dt91 | 2353 | Berberine | 7150 | TOP1 | Homo sapiens (human) | 23747414 | Berberine results in decreased activity of TOP1 protein |
| dt92 | 2353 | Berberine | 7153 | TOP2A | Homo sapiens (human) | 23747414 | TOP2A protein affects the susceptibility to berberine|top2a protein affects the reaction [berberine results in increased expression of H2AX protein modified form] |
| dt93 | 2353 | Berberine | 7157 | TP53 | Homo sapiens (human) | 26712469 | Berberine results in increased phosphorylation of and results in increased acetylation of TP53 protein|[berberine co-treated with niacinamide] results in increased expression of and results in increased acetylation of TP53 protein |
| dt94 | 2353 | Berberine | 7157 | TP53 | Homo sapiens (human) | 20656010 | Berberine results in increased expression of TP53 mrna|berberine results in increased expression of TP53 protein |
| dt95 | 2353 | Berberine | 7186 | TRAF2 | Mus musculus (house mouse) | 30240693 | Berberine inhibits the reaction [[lipopolysaccharide, escherichia coli O111 B4 co-treated with TNF protein] results in increased secretion of TRAF2 protein]|berberine inhibits the reaction [[lipopolysaccharide, escherichia coli O111 B4 co-treated with TNF |
| dt96 | 2353 | Berberine | 6737 | TRIM21 | Homo sapiens (human) | 36822301 | Berberine promotes the reaction [IGF2BP3 protein binds to TRIM21 protein] |
| dt97 | 2353 | Berberine | 100131187 | TSTD1 | Homo sapiens (human) | 27311644 | Berberine results in increased expression of TSTD1 mRNA |
| dt98 | 2353 | Berberine | 7319 | UBE2A | Homo sapiens (human) | 27311644 | Berberine results in decreased expression of UBE2A mRNA |
| dt99 | 2353 | Berberine | 7320 | UBE2B | Homo sapiens (human) | 27311644 | Berberine results in decreased expression of UBE2B mRNA |
- No data available
Phase Distribution
Phase Description
- Phase 0: Exploratory trials to assess drug behavior in humans
- Phase 1: Safety trials to determine safe dosage range
- Phase 2: Efficacy trials to evaluate therapeutic effects
- Phase 3: Large-scale trials to confirm efficacy and safety
- Phase 4: Post-marketing surveillance for long-term safety and efficacy
| Trial ID | Title | Phase | Status | Sponsor | Indications | Interventions | |
|---|---|---|---|---|---|---|---|
| NCT02962245 | Efficacy of Treatment With Berberine to Maintain Remission in Ulcerative Colitis | PHASE4 | WITHDRAWN | Xijing Hospital of Digestive Diseases | Ulcerative Colitis | DRUG: berberine|DRUG: regular treatment | Details |
| ChiCTR2400083224 | A clinical trial to evaluate the relationship between nitric oxide content in type 3 natural lymphocytes and severity of enteritis and response to drug intervention in patients with inflammatory bowel disease | Not Available | Not Recruiting | Peking University Third Hospital | Inflammatory Bowel Disease | Trial group:Berberine hydrochloride tablets mesa… | Details |
| NCT02365480 | Berberine Chloride in Preventing Colorectal Cancer in Patients With Ulcerative Colitis in Remission | PHASE1 | COMPLETED | National Cancer Institute (NCI) | Ulcerative Colitis | DRUG: Berberine Chloride|OTHER: Laboratory Biomar… | Details |
| NCT04985968 | The Efficacy and Safety of Cobitolimod in Participants With Moderate to Severe Active Left-Sided Ulcerative Colitis | PHASE3 | TERMINATED | InDex Pharmaceuticals | Ulcerative Colitis | DRUG: Cobitolimod 250 mg|DRUG: Cobitolimod 500 mg… | Details |
| NCT06681181 | A First-time in Human (FTIH) Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK4528287 in Healthy Participants | PHASE1 | RECRUITING | GlaxoSmithKline | Colitis, Ulcerative | DRUG: GSK4528287|DRUG: Placebo | Details |
| NCT05992142 | ChAracterizing the Remission Status in Patients With Ulcerative Colitis Treated by 5-ASA | PHASE4 | COMPLETED | Belgian Inflammatory Bowel Disease Research and Development (BIRD) VZW | Ulcerative Colitis | DRUG: 5-ASA | Details |
| NCT00787202 | A Study To Investigate The Safety And Efficacy Of CP- 690,550 In Patients With Moderate And Severe Ulcerative Colitis. | PHASE2 | COMPLETED | Pfizer | Ulcerative Colitis | DRUG: CP- 690 550|DRUG: CP- 690 550|DRUG: CP- 690… | Details |
| NCT06321887 | EffiCacy and sAfEty of Low doSe orAl iRon for Anaemia in IBD | PHASE3 | RECRUITING | Liverpool University Hospitals NHS Foundation Trust | Inflammatory Bowel Disease|Iron Deficiency Anemia | DRUG: Ferrous fumarate syrup 2.5ml/70mg (22.5mg e… | Details |
| NCT00207688 | A Long Term Safety Study of Infliximab (Remicade) in in Ulcerative Colitis Patients | None | COMPLETED | Janssen Research & Development, LLC | Ulcerative Colitis | DRUG: Infliximab 5 mg/kg|DRUG: Infliximab 10 mg/k… | Details |
| NCT04677179 | A Study of LY3471851 in Adult Participants With Moderately to Severely Active Ulcerative Colitis (UC) | PHASE2 | TERMINATED | Nektar Therapeutics | Colitis, Ulcerative | DRUG: LY3471851|DRUG: Placebo | Details |
| NCT02958865 | Study to Compare Oral PF-06651600, PF-06700841 and Placebo in Subjects With Moderate to Severe Ulcerative Colitis | PHASE2 | COMPLETED | Pfizer | Ulcerative Colitis | DRUG: PF-06651600 or Placebo|DRUG: PF-06700841 or… | Details |
| NCT03943550 | Double-Blinded, Placebo-Controlled Phase 1b Study for Safety, PK, Efficacy, PD of RO7049665 in Participants With Ulcerative Colitis (UC) | PHASE1 | TERMINATED | Hoffmann-La Roche | Ulcerative Colitis | DRUG: RO7049665|DRUG: Placebo | Details |
| NCT02840721 | Safety, Efficacy, and Tolerability Study of PF-06480605 in Subjects With Moderate to Severe Ulcerative Colitis. | PHASE2 | COMPLETED | Telavant, Inc. | Colitis, Ulcerative | DRUG: PF-06480605 | Details |
| NCT04133194 | Adherence of a 1.600 mg Single Tablet 5-ASA Treatment of Ulcerative Colitis | PHASE4 | RECRUITING | Flemming Bendtsen | Ulcerative Colitis | DRUG: Mesalazine|DRUG: Mesalazine | Details |
| NCT01465763 | A Study Evaluating The Efficacy And Safety Of CP-690,550 In Patients With Moderate To Severe Ulcerative Colitis | PHASE3 | COMPLETED | Pfizer | Ulcerative Colitis | DRUG: tofacitinib|DRUG: Placebo | Details |
| NCT06636656 | A Study to Test Whether BI 3032950 Helps People With Ulcerative Colitis | PHASE2 | RECRUITING | Boehringer Ingelheim | Ulcerative Colitis | DRUG: BI 3032950 intravenous (Part A)|DRUG: BI 30… | Details |
| NCT04996797 | A Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Moderately to Severely Active Ulcerative Colitis (MK-7240-005) | PHASE2 | ACTIVE_NOT_RECRUITING | Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Ulcerative Colitis | DRUG: Tulisokibart|DEVICE: Companion Diagnostic (… | Details |
| NCT01458951 | A Study To Evaluate Both The Efficacy and Safety Profile of CP-690,550 In Patients With Moderately to Severely Active Ulcerative Colitis | PHASE3 | COMPLETED | Pfizer | Ulcerative Colitis | DRUG: tofacitinib|DRUG: Placebo | Details |
| NCT04499495 | Assessment of 5-Aminosalicylic Acid Prescription Patterns and Treatment Outcomes in Patients With Ulcerative Colitis in Korea | None | COMPLETED | Ferring Pharmaceuticals | Ulcerative Colitis | OTHER: PENTASA (mesalamine/ 5-Aminosalicylic acid… | Details |
| NCT01959282 | A Study of Safety and Effectiveness of JNJ-54781532 in Patients With Moderately to Severely Active Ulcerative Colitis | PHASE2 | COMPLETED | Janssen Research & Development, LLC | Colitis, Ulcerative | DRUG: Placebo|DRUG: JNJ-54781532 25 mg once daily… | Details |
| Disease ID | Disease Name | Definition | Category | Related Drugs | Mechanism | |
|---|---|---|---|---|---|---|
| No data available | ||||||
| Strategy ID | Therapeutic Strategy | Synonyms | Related Drugs | Mechanism | |
|---|---|---|---|---|---|
| S01 | Anti-inflammatory | inflammatory | 5-Aminosalicylates (5-ASAs); corticosteroids | Crohn's disease and ulcerative colitis are the two main com… | Details |
| S06 | Anti-fibrosis | fibrosis; tissue remodelling | GS-5745; STNM01 | Tissue remodelling and destruction in patients with IBD is … | Details |
| S07 | Blockade of cytokine | Cytokine signalling | apremilast; roflumilast; filgotinib; tofacitinib; ABT494; ABT-874; ustekinumab; isankizumab; LY-2525623; AMG139; MEDI2079; guselkumab | Various T-cell subsets, their differentiation pathways and … | Details |
Oxyberberine ameliorates TNBS-induced colitis in rats through suppressing infla…
PMID: 37247589
Year: 2023
Relationship Type:
Treatment
Score: 9.5
BACKGROUND: Ulcerative colitis (UC) is a chronic, unspecific inflammatory bowel disorder lacking effective therapeutic targets and radical drugs. Oxy…
Berberine a traditional Chinese drug repurposing: Its actions in inflammation-a…
PMID: 36561763
Year: 2022
Relationship Type:
Treatment
Score: 9.5
Berberine (BBR), an isoquinoline alkaloid extracted from Coptidis Rhizoma, has a long history of treating dysentery in the clinic. Over the past two …
Berberine increases stromal production of Wnt molecules and activates Lgr5(+) s…
PMID: 36528592
Year: 2022
Relationship Type:
Treatment
Score: 9.5
BACKGROUND: Inflammatory bowel diseases (IBDs) are characterized by sustained inflammation and/or ulcers along the lower digestive tract, and have co…
Macrophage-Targeted Berberine-Loaded β-Glucan Nanoparticles Enhance the Treatme…
PMID: 36406639
Year: 2022
Relationship Type:
Treatment
Score: 9.5
AIM: This study focuses on constructing of an anti-inflammatory drug delivery system by encapsulation of berberine in the beta-glucan nanoparticles a…
A Randomized, Dose-Finding, Proof-of-Concept Study of Berberine Ursodeoxycholat…
PMID: 36327436
Year: 2022
Relationship Type:
Treatment
Score: 9.5
INTRODUCTION: Primary sclerosing cholangitis (PSC) is a fibroinflammatory disease of the bile ducts leading to cirrhosis and hepatic decompensation. …
Berberine Depresses Inflammation and Adjusts Smooth Muscle to Ameliorate Ulcera…
PMID: 36287004
Year: 2022
Relationship Type:
Treatment
Score: 9.5
Intestinal microbiota dysbiosis is a well established characteristic of ulcerative colitis (UC). Regulating the gut microbiota is an effective UC tre…
Demethyleneberberine blocked the maturation of IL-1β in inflammation by inhibit…
PMID: 36252484
Year: 2022
Relationship Type:
Mechanism
Score: 9.5
Demethyleneberberine (DMB) is a natural product from traditional Chinese medicinal herb the rhizome of Coptis chinensis Franch., which has been repor…
Effect and Mechanism of Pharmaceutical Excipients on Berberine to Alleviate Ulc…
PMID: 36144733
Year: 2022
Relationship Type:
Treatment
Score: 9.5
BACKGROUND: Various potential effect of drugs on alleviating diseases by regulating intestinal microbiome as well as the pharmaceutical excipients on…
Targeted delivery of Chinese herb pair-based berberine/tannin acid self-assembl…
PMID: 36100331
Year: 2022
Relationship Type:
Treatment
Score: 9.5
INTRODUCTION: Ulcerative colitis (UC) is a chronic recurrent idiopathic disease characterized by damage to the colonic epithelial barrier and disrupt…
[Experimental study on effects of berberine combined with 6-shogaol on intestin…
PMID: 36046871
Year: 2022
Relationship Type:
Treatment
Score: 9.5
Cold-heat combination is a common method in the treatment of ulcerative colitis, which is represented by classic drug pair, Coptidis Rhizoma and Zing…
A Combination of Baicalin and Berberine Hydrochloride Ameliorates Dextran Sulfa…
PMID: 35980327
Year: 2022
Relationship Type:
Treatment
Score: 9.5
Baicalin and berberine hydrochloride are the main chemical compositions of Scutellariae Radix and Coptidis Rhizoma, respectively. S. Radix and C. Rhi…
Therapeutic Mechanisms of Berberine to Improve the Intestinal Barrier Function …
PMID: 35935245
Year: 2022
Relationship Type:
Treatment
Score: 9.5
BACKGROUND: Inflammatory bowel disease (IBD), a disease that seriously harms human and animal health, has attracted many researchers' attention becau…
Berberine Ameliorates Dextran Sulfate Sodium-Induced Ulcerative Colitis and Inh…
PMID: 35893243
Year: 2022
Relationship Type:
Treatment
Score: 9.5
Ulcerative colitis (UC) is one of the primary types of inflammatory bowel disease, the occurrence of which has been increasing worldwide. Research in…
Protective effect of berberine against LPS-induced injury in the intestine: a r…
PMID: 35852392
Year: 2022
Relationship Type:
Mechanism
Score: 9.5
Sepsis is a systemic inflammatory condition caused by an unbalanced immunological response to infection, which affects numerous organs, including the…
Mucus-Penetrating Alginate-Chitosan Nanoparticles Loaded with Berberine Hydroch…
PMID: 35761150
Year: 2022
Relationship Type:
Treatment
Score: 9.5
The rectal enemas of berberine hydrochloride (BH) have emerged as one of the most effective strategies in the clinical treatment of ulcerative coliti…
Research on the mechanism of berberine in the treatment of COVID-19 pneumonia p…
PMID: 35403089
Year: 2022
Relationship Type:
Treatment
Score: 9.5
Purpose Pulmonary fibrosis caused by COVID-19 pneumonia is a serious complication of COVID-19 infection, there is a lack of effective treatment metho…
Concerted action of berberine in the porcine intestinal epithelial model IPEC-J…
PMID: 35384371
Year: 2022
Relationship Type:
Treatment
Score: 9.5
The plant alkaloid berberine has been shown to have many beneficial effects on human health. This has led to its use as a treatment for various cance…
Berberine ameliorates DSS-induced intestinal mucosal barrier dysfunction throug…
PMID: 35280677
Year: 2022
Relationship Type:
Treatment
Score: 9.5
Ulcerative colitis (UC) is an idiopathic, chronic inflammatory disorder of the colon, and it has become one of the world-recognized medical problems …
Berberine represses Wnt/β-catenin pathway activation via modulating the microRN…
PMID: 35259053
Year: 2022
Relationship Type:
Treatment
Score: 9.5
Intestinal barrier dysfunction is inflammatory bowel disease's hallmark. Berberine (BBR) has manifested its anti-inflammatory properties in colitis. …
Berberine suppresses cecal ligation and puncture induced intestinal injury by e…
PMID: 35158228
Year: 2022
Relationship Type:
Treatment
Score: 9.5
The gut is hypothesized to be the "motor" of critical illness and plays an important role in the development of sepsis. Berberine (BBR) is an alkaloi…